Please use this identifier to cite or link to this item:
Title: Novel synthetic polymyxins kill Gram-positive bacteria
Author: Rudilla Mateo, Héctor
Perez-Guillén, I.
Rabanal Anglada, Francesc
Sierra Ortigosa, Josep Maria
Vinuesa Aumedes, Teresa
Viñas, Miquel
Keywords: Biofilms
Infeccions nosocomials
Agents antiinfecciosos
Nosocomial infections
Anti-infective agents
Issue Date: 6-Aug-2018
Publisher: Oxford University Press
Abstract: Background: Staphylococcus aureus, including 'superbug' MRSA, is a major cause of nosocomial infections. In the European Union, up to 171 200 new nosocomial MRSA infections are acquired annually, and in the USA S. aureus causes more deaths than HIV/AIDS and tuberculosis combined. MRSA is also the first group of pathogens that infect the pulmonary tract in young patients with cystic fibrosis. Objectives: We describe two newly developed and synthesized colistin (polymyxin E)-inspired molecules. Methods: A collection of several isolates of S. aureus [including MRSA and vancomycin-resistant S. aureus (VRSA)] was tested. To check the antimicrobial activity, we performed time-kill curves, growth curves, biofilm eradication, toxicity and isothermal titration calorimetry. Results: Both peptides showed high antimicrobial activities (MIC 4 mg/L) and low relative toxicities (selectivity index close to 23). Conclusions: Successful production of polymyxin-scaffold molecules active against S. aureus, both MRSA and VRSA, opens up new approaches to the treatment of these complicated infections.
Note: Versió postprint del document publicat a:
It is part of: Journal of Antimicrobial Chemotherapy, 2018, vol. 73, num. 12, p. 3385-3390
Related resource:
ISSN: 0305-7453
Appears in Collections:Articles publicats en revistes (Química Inorgànica i Orgànica)

Files in This Item:
File Description SizeFormat 
682097.pdf1.18 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.